1-11 of 11
Maha Hussain
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)

Maha Hussain, Masha Kocherginsky, Neeraj Agarwal, Nabil Adra, Jingsong Zhang, Channing J. Paller, Joel Picus, Zachery R. Reichert, Russell Z. Szmulewitz, Scott T. Tagawa, Timothy M. Kuzel, Latifa A. Bazzi, Stephanie Daignault-Newton, Young E. Whang, Robert Dreicer, Ryan D. Stephenson, Matthew B. Rettig, Daniel Shevrin, Travis Gerke, Arul M. Chinnaiyan, Emmanuel S. Antonarakis
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (19): 4318–4328.
https://doi.org/10.1158/1078-0432.CCR-24-1402
Published: 01 October 2024
View article titled, Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)
Open the PDF for Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway) in another window
Includes: Supplementary data
Journal Articles

Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA

Nobuaki Matsubara, Johann de Bono, David Olmos, Giuseppe Procopio, Satoru Kawakami, Yüksel Ürün, Robbert van Alphen, Aude Flechon, Michael A. Carducci, Young Deuk Choi, Sebastien J. Hotte, Ernesto Korbenfeld, Gero Kramer, Neeraj Agarwal, Kim N. Chi, Simon Dearden, Christopher Gresty, Jinyu Kang, Christian Poehlein, Elizabeth A. Harrington, Maha Hussain
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (1): 92–99.
https://doi.org/10.1158/1078-0432.CCR-21-3577
Published: 04 January 2023
View article titled, Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and <em>BRCA1, BRCA2</em>, or <em>ATM</em> Alterations Identified by Testing Circulating Tumor DNA
Open the PDF for Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and <em>BRCA1, BRCA2</em>, or <em>ATM</em> Alterations Identified by Testing Circulating Tumor DNA in another window
Includes: Supplementary data
Journal Articles

Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)

Maha Hussain, Claire Corcoran, Caroline Sibilla, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Joaquin Mateo, David Olmos, Niven Mehra, Michael P. Kolinsky, Guilhem Roubaud, Mustafa Özgüroǧlu, Nobuaki Matsubara, Craig Gedye, Young Deuk Choi, Charles Padua, Alexander Kohlmann, Robert Huisden, Julia A. Elvin, Jinyu Kang, Carrie A. Adelman, Allison Allen, Christian Poehlein, Johann de Bono
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1518–1530.
https://doi.org/10.1158/1078-0432.CCR-21-3940
Published: 14 April 2022
View article titled, Tumor Genomic Testing for &gt;4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)
Open the PDF for Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib) in another window
Includes: Supplementary data
Journal Articles

A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer

Phillip L. Palmbos, Stephanie Daignault-Newton, Scott A. Tomlins, Neeraj Agarwal, Przemyslaw Twardowski, Alicia K. Morgans, Wm. Kevin Kelly, Vivek K. Arora, Emmanuel S. Antonarakis, Javed Siddiqui, Jon A. Jacobson, Matthew S. Davenport, Dan R. Robinson, Arul M. Chinnaiyan, Karen E. Knudsen, Maha Hussain
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (11): 3017–3027.
https://doi.org/10.1158/1078-0432.CCR-21-0024
Published: 01 June 2021
View article titled, A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer
Open the PDF for A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer in another window
Journal Articles

Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer

Maha Hussain, Sylvestre Le Moulec, Claude Gimmi, Rolf Bruns, Josef Straub, Kurt Miller
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (13): 3192–3200.
https://doi.org/10.1158/1078-0432.CCR-15-2512
Published: 30 June 2016
View article titled, Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer
Open the PDF for Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Molecular Pathways: Targeting ETS Gene Fusions in Cancer

Felix Y. Feng, J. Chad Brenner, Maha Hussain, Arul M. Chinnaiyan
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (17): 4442–4448.
https://doi.org/10.1158/1078-0432.CCR-13-0275
Published: 01 September 2014
View article titled, Molecular Pathways: Targeting ETS Gene Fusions in Cancer
Open the PDF for Molecular Pathways: Targeting ETS Gene Fusions in Cancer in another window
Journal Articles

Phase II Study of Single-Agent Orteronel (TAK-700) in Patients with Nonmetastatic Castration-Resistant Prostate Cancer and Rising Prostate-Specific Antigen

Maha Hussain, Paul G. Corn, M. Dror Michaelson, Hans J. Hammers, Joshi J. Alumkal, Charles J. Ryan, Justine Y. Bruce, Susan Moran, Shih-Yuan Lee, H. Mark Lin, Daniel J. George, for the Prostate Cancer Clinical Trials Consortium, a program of the Department of Defense Prostate Cancer Research Program and the Prostate Cancer Foundation
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (16): 4218–4227.
https://doi.org/10.1158/1078-0432.CCR-14-0356
Published: 13 August 2014
View article titled, Phase II Study of Single-Agent Orteronel (TAK-700) in Patients with Nonmetastatic Castration-Resistant Prostate Cancer and Rising Prostate-Specific Antigen
Open the PDF for Phase II Study of Single-Agent Orteronel (TAK-700) in Patients with Nonmetastatic Castration-Resistant Prostate Cancer and Rising Prostate-Specific Antigen in another window
Includes: Supplementary data
Journal Articles

Phase 2 Study of ABT-510 in Patients with Previously Untreated Advanced Renal Cell Carcinoma

Scot Ebbinghaus, Maha Hussain, Nizar Tannir, Michael Gordon, Apurva A. Desai, Raymond A. Knight, Rod A. Humerickhouse, Jiang Qian, Gary B. Gordon, Robert Figlin
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (22): 6689–6695.
https://doi.org/10.1158/1078-0432.CCR-07-1477
Published: 15 November 2007
View article titled, Phase 2 Study of ABT-510 in Patients with Previously Untreated Advanced Renal Cell Carcinoma
Open the PDF for Phase 2 Study of ABT-510 in Patients with Previously Untreated Advanced Renal Cell Carcinoma in another window
Journal Articles

Her-2/ neu Overexpression in Muscle-invasive Urothelial Carcinoma of the Bladder: Prognostic Significance and Comparative Analysis in Primary and Metastatic Tumors

Rafael E. Jimenez, Maha Hussain, Fernando J. Bianco, Jr., Ulka Vaishampayan, Pam Tabazcka, Wael A. Sakr, J. Edson Pontes, David P. Wood, Jr., David J. Grignon
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (8): 2440–2447.
Published: 01 August 2001
View article titled, Her-2/ <em>neu</em> Overexpression in Muscle-invasive Urothelial Carcinoma of the Bladder: <subtitle>Prognostic Significance and Comparative Analysis in Primary and Metastatic Tumors</subtitle>
Open the PDF for Her-2/ <em>neu</em> Overexpression in Muscle-invasive Urothelial Carcinoma of the Bladder: <subtitle>Prognostic Significance and Comparative Analysis in Primary and Metastatic Tumors</subtitle> in another window
Journal Articles

Phase II Study of Dolastatin-10 in Patients with Hormone-refractory Metastatic Prostate Adenocarcinoma

Uika Vaishampayan, Michael Glode, Wei Du, Andrew Kraft, Gary Hudes, Jeremy Wright, Maha Hussain
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (11): 4205–4208.
Published: 01 November 2000
View article titled, Phase II Study of Dolastatin-10 in Patients with Hormone-refractory Metastatic Prostate Adenocarcinoma
Open the PDF for Phase II Study of Dolastatin-10 in Patients with Hormone-refractory Metastatic Prostate Adenocarcinoma in another window
Journal Articles

Cellular Proliferation and Prevalence of Micrometastatic Cells in the Bone Marrow of Patients with Clinically Localized Prostate Cancer

Michael L. Cher, Jose G. de Oliveira, Andrew A. Beaman, Jeffrey A. Nemeth, Maha Hussain, David P. Wood, Jr.
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (9): 2421–2425.
Published: 01 September 1999
View article titled, Cellular Proliferation and Prevalence of Micrometastatic Cells in the Bone Marrow of Patients with Clinically Localized Prostate Cancer
Open the PDF for Cellular Proliferation and Prevalence of Micrometastatic Cells in the Bone Marrow of Patients with Clinically Localized Prostate Cancer in another window